GET DAILY SIGNALSBiogen (BIIB) Advances +10.8% Over the Past 30 Days on Strong Q3 Results
Key Takeaways
- BIIB shares climbed roughly +10.8% over the trailing 30 days, rising from a $227.07 close on September 29 to about $251.59.
- Third-quarter 2026 results, reported on October 28, beat consensus, with revenue of $2.80 billion (up 11% year over year) and adjusted EPS of $2.62 versus the roughly $2.06 expected.
- Biogen's Growth Portfolio revenue rose 49% to $1.26 billion and now represents about 63% of core pharmaceutical revenue, supported by the first full quarter of Apellis products.
- The company raised the lower end of its full-year 2026 non-GAAP EPS guidance to a range of $12.20 to $13.00.
- The advance extends beyond one month: the stock is up roughly 20% over the trailing quarter and about 44% year to date.
- Get additional detail on Biogen's Price Targets, Earnings, and Forecast to see how analysts and data models view the name.
- Explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.
Biogen's Focus and Market Standing
Biogen Inc. operates as a global biotechnology firm based in Cambridge, Massachusetts, with a core emphasis on therapies for neurological and rare diseases. Its lineup includes multiple sclerosis treatments like Tysabri and Vumerity, the spinal muscular atrophy option Spinraza, the Alzheimer's therapy Leqembi developed alongside Eisai, and the Friedreich ataxia drug Skyclarys, plus Qalsody and Zurzuvae. The May 2026 acquisition of Apellis brought in the geographic atrophy treatment Syfovre and the complement inhibitor Empaveli. Investors track BIIB for its neurology and immunology pipeline updates, the shift away from a maturing multiple sclerosis business, and the potential for newer products to sustain revenue growth.
Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, Biogen shares moved from a closing price of $227.07 on September 29, 2026, to roughly $251.59, for a gain of about +10.8%. The upward move picked up pace in the latter half of October, lifting the stock from around $233 in mid-October into the mid-$250s following the earnings release before settling near $251. The quarterly view shows even more strength. From a close of $209.23 on July 29, 2026, the shares have risen approximately 20%, pointing to a steady trend rather than a one-day jump. This aligns with the year-to-date advance of roughly 44%, which has outpaced the broader market as the growth portfolio gained traction. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Beat and Recent Price Drivers
The main catalyst came from Biogen's third-quarter 2026 earnings release on October 28. Revenue reached $2.80 billion, up 11% year over year and above consensus estimates of roughly $2.59 billion to $2.64 billion. Adjusted earnings per share of $2.62 topped the approximately $2.06 analysts had projected, marking a solid positive surprise. Newer products supported the beat. Spinraza revenue increased 23% to $461 million amid quick uptake of the high-dose regimen, while Leqembi in-market sales rose 67% to $202 million and Skyclarys grew 34% to $178 million. Syfovre and Empaveli from the Apellis deal added a combined $243 million in their first full quarter, with management noting the pair was on track for roughly a $1 billion annualized run rate. Biogen also lifted the lower end of its 2026 non-GAAP EPS guidance to $12.20, reflecting business strength and faster-than-expected integration. Some offsets appeared in the report, including a GAAP net loss of $20.6 million tied to about $284 million in acquired in-process R&D charges, mainly from the RayThera deal, and ongoing pressure on the legacy multiple sclerosis franchise. Still, analyst actions after the quarter leaned positive, with a Buy rating from Piper Sandler and other firms reiterating coverage.
Quarterly Momentum and Supporting Factors
Over the trailing quarter, Biogen's progress reflects a broader return-to-growth story. Completion of the Apellis acquisition in May 2026 broadened the revenue base into ophthalmology and nephrology, and integration has moved quicker than first expected, with management aiming for $250 million in run-rate cost synergies by the end of 2027. Solid execution across Spinraza, Leqembi, Skyclarys, and the acquired products has shifted the revenue mix, with the growth portfolio now making up nearly two-thirds of core pharmaceutical revenue. A deep late-stage pipeline has also drawn investor interest. Management has pointed to several registrational readouts ahead, including Phase 3 data for litifilimab in systemic lupus erythematosus and later updates for felzartamab and zorevunersen. This mix of improving commercial results and near-term catalysts has helped sustain the upward path through the quarter. From what I see, the pipeline timing lines up well with the commercial progress.
Key Items to Monitor Ahead
Several elements should influence Biogen's near-term direction. December readouts from litifilimab's two Phase 3 systemic lupus erythematosus studies stand out as an important pipeline event, followed by data for felzartamab and later zorevunersen in Dravet syndrome. On the commercial front, attention will turn to whether Leqembi and the Apellis products maintain their growth pace and whether pressures on the multiple sclerosis franchise ease. Progress on cost synergies, debt reduction, and the full-year 2026 non-GAAP EPS range of $12.20 to $13.00 will also draw focus, along with any regulatory updates or sector-wide conditions.
My Take on Tickeron’s Trending AI Robots
I often review Tickeron’s Trending AI Robots page when looking at market positioning for names like this one. It curates top-performing AI-powered trading bots across strategies and timeframes, helping focus on signals that have shown recent strength without sifting through every option. This offers a useful data-driven layer alongside fundamental work for investors aligning approaches with their own goals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for BIIB shows an upward move is likely
BIIB's Aroon Indicator triggered a bullish signal on October 26, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 197 similar instances where the Aroon Indicator showed a similar pattern. In 121 of the 197 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 61%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BIIB as a result. In 48 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on October 13, 2026. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in 35 of 59 cases over the following month. The odds of a continued upward trend are 59%.
Following a +0.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 167 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The 10-day RSI Indicator for BIIB moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 19 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.913) is normal, around the industry mean (-2.729). P/E Ratio (42.967) is within average values for comparable stocks, (20.997). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor
Advertisement